Cargando…

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series

The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vijayan, Sooraj, Hwangbo, Kyungmin, Barkham, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757239/ https://www.ncbi.nlm.nih.gov/pubmed/35059197 http://dx.doi.org/10.1002/ccr3.5233

Ejemplares similares

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007)

Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009)

Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis
por: Lee, Shin-Seok, et al.
Publicado: (2021)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis
por: Krishnan, V. S. Gokul, et al.
Publicado: (2017)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Body mass index influences the response to infliximab in ankylosing spondylitis
por: Ottaviani, Sébastien, et al.
Publicado: (2012)

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
por: Elalouf, Ofir, et al.
Publicado: (2015)

Bone changes and curative effect of infliximab in patients with ankylosing spondylitis
por: Li, Linying, et al.
Publicado: (2020)

Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
por: Lorenzin, Mariagrazia, et al.
Publicado: (2015)

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis
por: Wang, Chenghai, et al.
Publicado: (2020)

Effectiveness and safety of secukinumab in ankylosing spondylitis: real-life data from Midlands Ankylosing Spondylitis Collaboration (MASC)
por: Ajibade, Adeola, et al.
Publicado: (2023)

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
por: Park, Won, et al.
Publicado: (2017)

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
por: Mulleman, Denis, et al.
Publicado: (2011)

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
por: Webers, Casper, et al.
Publicado: (2018)

Reducing work disability in Ankylosing Spondylitis – development of a work instability scale for AS
por: Gilworth, Gill, et al.
Publicado: (2009)

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
por: Yoo, Hyun Kyeong, et al.
Publicado: (2022)

Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy
por: Szalay, Balázs, et al.
Publicado: (2012)

Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
por: Moreno, Mireia, et al.
Publicado: (2019)

Cerebral Tuberculosis in a Patient Following Treatment With Infliximab for Ankylosing Spondylitis: A Case Report
por: Cretu, Ioana, et al.
Publicado: (2023)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Ankylosing Spondylitis
por: Whitfield, A. G. W.
Publicado: (1976)

Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab
por: Visvanathan, S, et al.
Publicado: (2008)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
por: Visvanathan, S, et al.
Publicado: (2008)

Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis
por: Aeberli, Daniel, et al.
Publicado: (2016)

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
por: Park, Won, et al.
Publicado: (2013)

Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score–Matched Analysis from the Korean College of Rheumatology Biologics Registry
por: Kim, Hyoun-Ah, et al.
Publicado: (2020)

Imaging of ankylosing spondylitis
por: Østergaard, Mikkel
Publicado: (2012)

Alexithymia in ankylosing spondylitis
por: Karabıçak, Deniz, et al.
Publicado: (2021)

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction
por: Baraliakos, X, et al.
Publicado: (2016)

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
por: Baraliakos, X, et al.
Publicado: (2005)

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
por: Morales-Lara, M J, et al.
Publicado: (2010)

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
por: Baji, Petra, et al.
Publicado: (2014)

Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)
por: Webers, Casper, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j8luj2kv7ehcl0g5hiched6l3j